March 30 (Reuters) - Cyclopharm Ltd (CYC) :
- ENTERED FINAL REVIEW PROCESS FOR ATTAINING USFDA APPROVAL TO COMMENCE COMMERCIAL SALES OF TECHNEGAS IN US MARKET IN 2023
- EXPECTS TO MAINTAIN ACTIVE DIALOGUE WITH USFDA IN SIX-MONTH REVIEW PERIOD
- SALES OF TECHNEGAS IN US ARE EXPECTED TO COMMENCE IN LATE 2023
News: CYC Cyclopharm Says Sales Of Technegas In U.S. Expected To Commence In Late 2023
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
81.0¢ |
Change
-0.030(3.57%) |
Mkt cap ! $90.02M | |||
| Open | High | Low | Value | Volume |
| 84.0¢ | 84.0¢ | 77.5¢ | $106.4K | 131.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9105 | 81.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.0¢ | 3208 | 2 |
View Market Depth
| Last trade - 13.21pm 11/09/2025 (20 minute delay) ? |
| CYC (ASX) Chart |